Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”
Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for ophthalmology. Since the original report was released, the first ophthalmology biosimilar–Byooviz™, from Biogen and Samsung Bioepis–launched in the United States.
In the report, Brill discusses lessons learned in other biosimilar markets. He also shares how to use these lessons to unlock the potential of ophthalmology biosimilars. The healthcare system could see significant savings as the first ophthalmology biosimilars enter the US market. Industry stakeholders need to be ready to overcome barriers to early adoption to increase access for deserving patients. Educating ophthalmologists, practice administrators, payers, and patients on the safety and efficacy of biosimilars will help support their early adoption.
Click here to read the full report on the MGA website.
